They found that several hit compounds containing extended planararomatic moieties could prevent the recruitment of TDP-43 and FUS into SGs, and proposed that compounds with planar moieties contain a target point for small-molecule therapy for ALS/FTD [113]. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.